Cardinal Health to acquire pharmaceutical distributor Kinray
DUBLIN, Ohio Cardinal Health is looking to expand the pharmaceutical segment of its business by acquiring a pharmaceutical distributor serving the New York metropolitan area.
The company said its acquisition of Kinray for $1.3 billion in an all-cash transaction would significantly expand its ability to serve retail independent pharmacies in the northeastern United States. Kinray currently serves more than 2,000 retail independent pharmacy customers as a distributor of both branded and generic pharmaceuticals.
After the transaction is complete, Kinray customers will be able to tap into a leading line of service offerings from Cardinal Health, Cardinal Health said.
"Adding Kinray to the Cardinal Health pharmaceutical segment portfolio will enable us to build on our increasing presence in community pharmacy and accelerate our growth in this important channel," said George Barrett, Cardinal Health chairman and CEO. "We are excited to have the Kinray employees join the Cardinal Health family, and we look forward to their contributions. Kinray has a long-standing service tradition with its customers. We intend to continue that tradition, utilizing its customer expertise and Whitestone distribution facility, while creating additional value for its customers through branded pharmaceutical programs, inventory and pharmacy management tools, and Cardinal Health’s extensive generic drug program."
Merck’s cardiovascular drug improves cholesterol levels in patients during late-stage trial
WHITEHOUSE STATION, N.J. Patients taking an investigational treatment for cardiovascular disease showed big improvements in cholesterol levels, according to late-stage clinical trial results released Wednesday.
Merck announced results of its 18-month phase-3 trial of anacetrapib in 1,623 patients with coronary heart disease. The drug showed no difference in safety compared with placebo, and 16 patients experienced cardiovascular problems –– cardiovascular death, heart attack, unstable angina or stroke –– compared with 21 taking placebo. Data were presented Wednesday at the scientific sessions of the American Heart Association and published online in the New England Journal of Medicine.
Most importantly, after 24 weeks of treatment among patients who had previously taken a statin, the drug decreased “bad” LDL cholesterol by 40% while increasing “good” HDL cholesterol by 138%.
Local independent pharmacy models program after NCPA’s Dispose My Meds
ALEXANDRIA, Va. — A group representing the nation’s independent pharmacies praised a local drug store’s participation in a drug take-back program.
The National Community Pharmacists Association lauded the Great Peconic Take Back event, held Wednesday, which served the eastern Suffolk area of New York. Led by Bob Grisnik of Southrifty Drug, located in Southampton, N.Y., the free service allowed anyone wishing to safely dispose of his or her expired or otherwise unwanted prescription and over-the-counter medications to bring the medications to any of the 15 participating pharmacies of the newly formed Peconic Independent Pharmacy Association.
The program is based on the NCPA’s Dispose My Meds program, which addresses drug diversion and environmental contamination.
“It’s exciting to see community pharmacies working together to meet the growing patient demand for a safe and environmentally friendly way to discard unused medications. Programs like this should be voluntary, but I hope many pharmacies seize the opportunity to create their own programs to meet the needs of their patients,” said Robert Greenwood, NCPA president.